NCT03198793View on ClinicalTrials.gov

Novel Evaluation With QGC001 in Hypertensive Overweight Patients of Multiple Ethnic Origins

PHASE2CompletedINTERVENTIONAL

Enrollment

256

Participants

Timeline

Start Date

October 13, 2017

Primary Completion Date

October 16, 2018

Study Completion Date

November 12, 2018

Conditions

Hypertension

Interventions

DRUG

QGC001

Twice daily (BID) administration of oral (PO) QGC001 (250 mg BID, 500 mg BID, and 500 mg BID + hydrochlorothiazide (HCTZ) 25 mg once daily \[QD\]) over 8 weeks.

Trial Locations (1)

32127

Progressive Medical Research, Port Orange

All Listed Sponsors

lead

Quantum Genomics SA

INDUSTRY

NCT03198793 - Novel Evaluation With QGC001 in Hypertensive Overweight Patients of Multiple Ethnic Origins | Biotech Hunter | Biotech Hunter